Zopiclone

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Zopiclone
   1. Pharmacist Assessment Report
   2. Zopiclone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Zopiclone: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Zopiclone, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is insomnia, which is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
insomnia (disease)	Licence in another country; approved indication: insomnia

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
13307J	Imovane	Tablet 7.5 mg	Valid

Safety Considerations

Contraindication-related conditions (from drug–disease knowledge graph data, not label text): liver failure, anxiety disorder, neurotic disorder, dysthymic disorder.

Drug Interactions: 100 potential interactions were identified, but none has a severity grading (all are recorded as “Unknown”). Examples include morphine, scopolamine, metformin, glimepiride, pantoprazole, omeprazole and prednisone. Clinical significance cannot be determined from this data, particularly for additive CNS depression with opioids.

Literature-derived cautions: dependence and abuse potential, rebound insomnia on discontinuation, next-day cognitive impairment, falls and car accidents (especially in older adults). Short-term use only (generally up to four weeks) is recommended.

Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---